Overview
Progressive myoclonus epilepsy with ataxia, often associated with Lafora disease, is characterized by the presence of Lafora bodies—accumulations of polyglucosan deposits—leading to severe neurological symptoms including myoclonus and cerebellar ataxia 12.Diagnosis
Presence of Lafora bodies in neuronal perikarya, dendrites, and notably in the cerebellar granular layer 12.
Histopathological examination of brain tissue, particularly cerebellum, is crucial for diagnosis 2.
Genetic testing for mutations in EPM2A (encoding laforin) or NHLRC1 (encoding malin) can confirm the diagnosis 1.Management
No specific curative treatments; management focuses on symptomatic relief 12.
Anticonvulsants such as valproate and levetiracetam may be used to control seizures 1.
Supportive care including physical and occupational therapy to manage ataxia and motor symptoms 1.Special Populations
Pediatrics: Early onset cases require close monitoring and multidisciplinary support 1.
Comorbidities: No specific guidance provided in the abstracts; general management principles apply 1.Key Recommendations
Perform histopathological examination of brain tissue, especially focusing on cerebellar regions, for Lafora bodies to confirm diagnosis (Evidence: Moderate 2).
Initiate anticonvulsant therapy with drugs like valproate or levetiracetam to manage seizure activity (Evidence: Expert opinion 1).
Incorporate supportive therapies including physical and occupational therapy to address motor impairments (Evidence: Expert opinion 1).References
1 Chan EM, Ackerley CA, Lohi H, Ianzano L, Cortez MA, Shannon P et al.. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Human molecular genetics 2004. link
2 Scelsi R, Mazzella GL, Lombardi M. Myoclonus epilepsy with cerebellar Lafora bodies. Report of a case. Journal of neurology, neurosurgery, and psychiatry 1976. link